NEW YORK (360Dx) – After establishing its first two tests to predict the risk of metastasis in two melanoma indications, Castle Biosciences is laying the foundation to expand its technology for use in cutaneous squamous cell carcinoma (sCCC).
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.